conference to second Welcome Thank you, Dyadic's quarter call. Ping.
active especially several period an was XXXX of quarter fronts. on for second The Dyadic
a day cost recognition our are that I gene performance development further gaining improve credibility additional to CX every we and result, biologic of as drugs, to The of and CX is vaccines, believe production biologic other scales. technology successfully further the As accelerate focus platform. our at lower we the continue expression flexible globally products and develop commercials
contract We quarter, past Research new extended this partnership our Center Luina and During Institute expanded Technical with of sublicensing and Alphazyme R&D Novovet, India, relationships signed new the deal industry. VTT strategic entered into the Bio, in with we Finland, of two VTT. Serum agreements, long-term our a
certain addition, platform. research our programs In data the productivity and of technology drive expectations from has to respect versatility our initial exceeded with CX
continued three As with express tier research a of top progress, just additionally, this and and scientific of another this result an, collaboration signed types different fully-funded data we to company pharmaceutical classes week our proteins.
development excited believe research sublicensing with that affiliates are potential to very in two XXXX. into of to addition are agreements to in CX Year-to-date discussed research These collaborations proof new entered nine addition technology we signed collaborations collaboration, XXXX in concept of have globally. reported earlier the one the above. four organization. the our the expanded bring the and collaboration further already CX may are one about They in potential the adoption who can that their this expand we of discussions their has of up-speed as throughout We
we several and agreement the IIBR; Biological of one on Tanabe with small-to-medium enter the of year and biotech pharmaceutical other this Israeli ongoing discussions announced are Consortium, into additional by the a of Based licensing deal, Pharma and research agreements we companies, end. Those academic number top three companies, signed non-disclosure Genomics we and/or Biology. is top-XX number of company, sized Structural date, having Research, four the agreements SGC, University Institute of tier Sanofi-Aventis, additional to Mitsubishi include Molecular the which previously institutions, have year another plus expect pharma for Oxford; Fraunhofer Center and USA to part
our is strong. Finally, position expanding, our financial while remains corporate profile
the Russell Microcap the quarter, NASDAQ, were up-listed to and the included we subsequently During Index. in
to As long-term visibility a result, value. in and Dyadic base, our community, is broaden well investment further enhance positioned our shareholder build the shareholder
and are September, We number and and growing. industry outreach our effect in announce we our participation will the several to as publicly starting will be advance. and investors see of participate the to In already other institutional investor appears in this of investor conferences,
and pipeline is funded our Our strong. activities. we well opportunities, no internal million pursue financial own position as $XX.X are With securities, and as development our investment of to debt, grade and cash in well
prevention our Now, into a health a we need This This and by sublicensing this various I and has agreement believe become on of We to companion with existing market. would you efficient They ailments is collaborations projects. an Luina drug a this comment pleased development. relationship. contract is CMO. our some developer exciting for certain of the and manufacturing drug of for us and an entering growing entered animals. targeted the update on productive ongoing develop are agreement to cost-effective first Australian-based treatment animal company, benefits organization, products rapidly like and characterized to Bio to with for the market very the is potential be
a in venture, will sales. Dyadic future XX%, formed own which royalty receive in products has from Novovet, targeted will Bio commercializing new CX, we we on Luina if produced and joint successful
platform successful process will low as return, successful our milestone molecular will begun enzymes. Alphazyme equity commercializing end will royalties Our a receive volume for CX of by it receive tech payments and the be if In completed we tech in stake in additionally the express a and and use The is with the CX Alphazyme to high already products. has sublicense grant Alphazyme technology, with we year. we Alphazyme, Alphazyme could expect CX CX X.X% the right cost agreement transfer upon developing manufacturing of our technology transfer
in two Serum form Dyadic four developer and is upside drugs. and payments. low these manufacturer equity providing we have cost royalty With of we companies and global a of whom India with Institute additional deals vaccines milestone have potential the with its development The of shareholders new biotech agreements, well-known and in interests now of the
Aside milestone upon showcase sales, of power from vaccines drugs to payments and which worldwide. the commence this arrangement the to terms accessible patients more potential to CX believe commercial technology has platform financial therefore and potential affordable of that more we make biologic the collaboration the and the
bioprocessing the to their and biology expertise as invaluable XXXX VTT our June research third-party already us of with of been end Near the well The we Research collaboration Center Serum in quarter, Finland, research covered by to our collaboration of of begun. Serum India. has additional opening support extended the for including second Sanofi applications molecular has providing and of collaborations Institute the our fungal as for pathways CX technology Technical
of already record expanding opportunities. different with productivity and types proteins has produced range together of our of growth several levels work Our is
Now some comments in our ongoing projects.
Regarding can of second our Sanofi, to the and This phase phase. collaborative have and be second completed we phase. higher effort truly is project the achieved we first a the expression levels during that move believe
the expression ZAPI, liter level. of against today, As with we the results fermentation with XX yield per ZAPI release times the further X,XXX of demonstrated antigen virus success announced with the we respect milligrams initially to have targeted or number of small in the
before end the trials CX express of the animal antigen begin to expect year. We the with
in CX. first success has its ZAPI based to incorporating with be of Additionally interest the second the project, in on antigen ZAPI antigen expressed express
is intend begin With certain us respect to threat. developed to being our to that Biological QX CX in Institute which collaboration biological a IIBR animal has of they immunogenicity Israeli his the informed the with of them Research, combat antigen, by the produced testing,
entered with previously of top reported an to earlier this pharmaceutical companies amendment XX As our I mentioned research earlier, we collaboration the into one expand year.
CRO other for of continuing as on we prime make to VTT, and our collaborators. programs third-party the progress internally At our as funded CX well ourselves are glycoengineering research
previously, also we CX an ongoing. started this internally research have funded develop train mentioned is the metabolite the project produce to and secondary to As
are be continuing early completed Certolizumab make expect At to developing by for now downstream XXXX. CX progress this BDI, in and to purification we process a
supply, we gene therapy are develop use express and AAV, potential to reported continuing for are Additionally, viral demand costly in to applications. selling high adeno-associated vectors short CX which and
to Today plan. unique our are world of initial terms our in in how growth progressing according business. science and development the somewhat In the we our this of of development summary, we biotech is project the approach
industries. develop We our of in have and and own on because goal to and of number its pipeline with company's and we shots for technology biotech growing a many develop as work internal and of derived applications a we our agencies further number apply governmental CX use institutes products growing biologically exciting other and continue academic pharmaceutical
in costs to production globally. CX a have broadly and our vision order We healthcare drugs performance the biologic accessible lower other patients improve more vaccines, of to technology accelerate affordable and applying to products make development, the of biologic and
We funded have we have and no this R&D R&D a year position and we strong several collaborations party expect financial debt. several third additional collaborations ongoing with funded
and mentioned vision and providing conferences of the be September active into and As both and insights will additional through meeting forward progress. industry in look at remainder I we our investor we year earlier, and to you
the turn I the back that, financial. to With call Ping to will review
